ICON Public Limited Company (NASDAQ:ICLR) faces delays in releasing earnings as it conducts an internal investigation into revenue recognition practices. Preliminary findings indicate a less than 2% revenue overstatement for 2023-2024, impacting adjusted EPS. The investigation is expected to conclude by April 30, 2026.

The Irish company provides outsourced services to the pharmaceutical industry, including clinical trial management and laboratory services. Despite being considered one of the best foreign stocks to buy, analysts believe other AI stocks may offer greater upside potential and less downside risk. Investors are urged to explore other opportunities.

Read more at Yahoo Finance: ICON Public Limited Company (ICLR) Delays Earnings Amid Internal Investigation